{
  "risk_score_0_to_1": 0.92,
  "confidence_0_to_1": 0.90,
  "dominant_mechanisms": [
    {"mechanism": "mitochondrial_dysfunction", "score_0_to_1": 0.90},
    {"mechanism": "reactive_metabolite_formation", "score_0_to_1": 0.85},
    {"mechanism": "cholestasis_bsep_inhibition", "score_0_to_1": 0.80},
    {"mechanism": "immune_mediated_injury", "score_0_to_1": 0.65},
    {"mechanism": "oxidative_stress", "score_0_to_1": 0.85}
  ],
  "time_to_onset": "subacute_weeks_to_months",
  "dose_dependence": "mixed_idiosyncratic_and_dose_related",
  "reversibility": "variable_some_irreversible",
  "uncertainties": [
    "Individual susceptibility factors poorly characterized despite extensive study",
    "Relative contribution of parent drug versus quinone metabolite unclear",
    "HLA associations not definitively established unlike other idiosyncratic hepatotoxins",
    "Why structurally similar glitazones (pioglitazone, rosiglitazone) show lower hepatotoxicity risk remains incompletely understood"
  ],
  "citations": [
    "Kohlroser J, et al. Hepatotoxicity due to troglitazone: report of two cases and review of adverse events reported to the FDA. Am J Gastroenterol. 2000;95(1):272-276.",
    "Smith MT. Mechanisms of troglitazone hepatotoxicity. Chem Res Toxicol. 2003;16(6):679-687.",
    "Funk C, et al. Troglitazone-induced intrahepatic cholestasis by an interference with the hepatobiliary export of bile acids in male rats. Toxicology. 2001;167(1):83-98."
  ]
}